As part of our ongoing aim to bring you reports of new developments, we have added a study review on the BE HEARD I and BE HEARD II trials which evaluated the efficacy and safety of bimekizumab, in adults with moderate-to-severe hidradenitis suppurativa.
Independent commentary for the review has been provided by Associate Professor John Frew, a fellow of the Australasian College of Dermatologists and researcher in the field of inflammatory skin diseases with a focus on hidradenitis suppurativa. He holds a staff specialist position at Liverpool Hospital and is a conjoint lecturer at the University of New South Wales.
Please login below to download this issue (PDF)